GSK committed $270 million up front in recent months to gain access to early-stage assets in the class of cancer therapies known as antibody drug conjugates, or ADCs. The deals are part of a broad ...
July 28 (Reuters) - Britain's GSK (GSK.L), opens new tab and China's Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab have agreed on a $500 million deal to develop up to a dozen new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback